Clinical Research Directory
Browse clinical research sites, groups, and studies.
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Sponsor: Peking Union Medical College Hospital
Summary
Researchers has conducted extensive research on the treatment of neuroendocrine tumors with 177Lu-EB-TATE and the treatment of FAP-expressing tumors with 177Lu-EB-FAPI, and some researches have revealed 68Ga-TATE-RGD in imaging studies of neuroendocrine tumors to find that the dual-targeted tracer showed an increasing TBR, suggesting the tracer kinetic advantage of TATE-RGD; compared to the single-target tracer DOTATATE, the dual-target TATE-RGD probe has a clear advantage in detecting liver metastases of NETs, and it can be explored for potential therapeutic uses of TATE-RGD in future studies and used for related companion diagnostics in targeted radioisotope therapy (RLT).
Official title: Therapeutic Efficiency and Response to 177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-09-01
Completion Date
2025-02-20
Last Updated
2024-10-15
Healthy Volunteers
No
Conditions
Interventions
177Lu-TATE-RGD
accepted intravenous injection of 177Lu-TATE-RGD
Locations (1)
Chinese Academy of Medical Science & Peking Union Medical College Hospital
Beijing, Beijing Municipality, China